- Home
- IBTA vs CRMD Comparison
IBTA vs CRMD Comparison
Compare IBTA & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- CRMD
- Stock Information
- Founded
- IBTA 2011
- CRMD 2006
- Country
- IBTA United States
- CRMD United States
- Employees
- IBTA N/A
- CRMD N/A
- Industry
- IBTA
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- IBTA
- CRMD Health Care
- Exchange
- IBTA Nasdaq
- CRMD Nasdaq
- Market Cap
- IBTA 926.1M
- CRMD 871.9M
- IPO Year
- IBTA 2024
- CRMD 2010
- Fundamental
- Price
- IBTA $28.97
- CRMD $10.81
- Analyst Decision
- IBTA Hold
- CRMD Strong Buy
- Analyst Count
- IBTA 9
- CRMD 7
- Target Price
- IBTA $38.75
- CRMD $17.86
- AVG Volume (30 Days)
- IBTA 275.6K
- CRMD 2.5M
- Earning Date
- IBTA 11-12-2025
- CRMD 11-12-2025
- Dividend Yield
- IBTA N/A
- CRMD N/A
- EPS Growth
- IBTA 2512.20
- CRMD N/A
- EPS
- IBTA 2.84
- CRMD 0.79
- Revenue
- IBTA $367,604,000.00
- CRMD $121,484,498.00
- Revenue This Year
- IBTA N/A
- CRMD $546.87
- Revenue Next Year
- IBTA $0.58
- CRMD $51.48
- P/E Ratio
- IBTA $10.17
- CRMD $13.62
- Revenue Growth
- IBTA 3.49
- CRMD 14970.29
- 52 Week Low
- IBTA $22.50
- CRMD $5.60
- 52 Week High
- IBTA $79.80
- CRMD $17.43
- Technical
- Relative Strength Index (RSI)
- IBTA 36.09
- CRMD 44.78
- Support Level
- IBTA $32.06
- CRMD $10.87
- Resistance Level
- IBTA $35.23
- CRMD $11.68
- Average True Range (ATR)
- IBTA 1.23
- CRMD 0.68
- MACD
- IBTA -0.60
- CRMD 0.03
- Stochastic Oscillator
- IBTA 2.14
- CRMD 9.80
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.